Lupus patients see no benefit from HCQ on COVID-19 outcomes

Long-term use of hydroxychloroquine (HCQ) in patients with SLE does not seem to prevent severe COVID-19, according to a small observational study from France. In a series of 17 patients with long-term SLE and confirmed SARS-CoV-2 infection, the median duration of HCQ use was 7.5 years. Yet despite the hype about HCQ as a wonder ...

Already a member?

Login to keep reading.

© 2021 the limbic